PORTLAND, Oregon, September 28, 2018 /PRNewswire/ --
Rise in incidence of infertility-related issues, increase in adoption of hCG in pain management & weight loss, and implementation of recombinant technology are expected to propel the growth of the global hCG market.
Allied Market Research published a report, titled, Human Chorionic Gonadotropin (hCG) Market by Technology (Natural Source Extraction and Recombinant Technology), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, and Others), and End User (Fertility Clinics, Research Institutes, and Others): Global Opportunity Analysis and Industry Forecast, 2017-2025. The report offers detailed insights on the top investment pockets, market size & share, driving forces & opportunities, strategic developments, and competitive landscape. According to the report, the global human chorionic gonadotropin (hCG) market garnered $688 million in 2017 and is expected to reach $1,239 million by 2025, growing at a CAGR of 7.6% from 2018 to 2025.
Surge in adoption of hCG in pain management & weight loss and increase in incidence of infertility-related issues drive the growth of the market. However, warnings and cautions issued by the USFDA regarding the side-effects of hCG therapy would restrain the market growth. Conversely, the implementation of recombinant technology would create new pathways for the market players in future.
Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/3418
Natural source extraction segment to generate the highest revenue by 2025
Natural source extraction segment contributed more than half of the total market share in 2017 and would remain dominant throughout the forecast period. This is due to their widespread applicability in treatment of infertility issues among men and women as well as other medical conditions such as cryptorchidism. However, the recombinant technology segment would register the fastest CAGR of 8.9% from 2018 to 2025, owing to the availability of recombinant hCGs in different dose strengths as a part of individualized therapy.
Female infertility treatment segment to remain dominant by 2025
The female infertility treatment segment accounted for nearly half of the total market share in 2017. This segment is expected to maintain its dominance by 2025, owing to increase in infertility-related issues such as polycystic ovary syndrome (PCOS). However, the male hypogonadism segment would register the fastest CAGR of 8.1% from 2018 to 2025 due to effectiveness of hCG in treatment of testosterone deficiency in men. The report also analyzes oligospermic treatment and other therapeutic areas.
Fertility clinics segment to continue its lead throughout the forecast period
Availability of a wide range of fertility treatments under a single roof along with government reimbursements has enabled the fertility clinics segment to account for more than half of the total market share in 2017. This trend is expected to continue throughout the forecast period. However, the research institutes segment would grow at the highest CAGR of 8.9% from 2018 to 2025, owing to increase in R&D activities focusing on the usage of hCG in infertility treatment and their possible treatments such as in-vitro fertilization (IVF).
For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/3418
Asia-Pacific to grow the fastest
Asia-Pacific is expected to register the fastest CAGR of 9.4% from 2018 to 2025 owing to increase in investments by key players for the development of hCG injectable for countering infertility issues, surge in infertile population, and rise in awareness regarding treatment options for infertility. However, North America contributed more than one-third of the total market share in 2017, owing to significant rise in infertility issues arising due to improper functioning of hCG hormone.
Leading market players
The major companies analyzed in the research include Bristol Myers Squibb Company, Ferring B.V., Merck & Co., Inc., Cigna, Fresenius Kabi AG, Lee BioSolutions Inc., Sun Pharmaceutical Industries Ltd., Scripps Laboratories, Sanzyme, and Lupin AB. Collaborations, expansions, partnerships, joint ventures, mergers & acquisitions, and other strategies have been adopted by them to gain a stronghold in the industry.
Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree
Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
SOURCE Allied Market Research